BN 006 / Botanix Pharma - LARVOL DELTA

NRG-BN006 Training Session (NRG 2020) - No abstract available

NRG Oncology NRG-BN006: A phase II/III randomized, open-label study of Toca 511 and Toca FC with standard of care compared to standard of care in patients with newly diagnosed glioblastoma (SNO 2019) - "Toca 511 (vocimagene amiretrorepvec) is a retroviral replicating vector encoding a codon optimized, heat stabilized cytosine deaminase that converts Toca FC (extended-release 5- fluorocytosine,5-FC) into 5-fluorouracil. NRG-BN006 is anticipated to start enrollment in Q4 2019.  Supported by grants U10CA180868, U10CA180822 from NCI and Tocagen."

Clinical • P2/3 data

"Looking forward to the BN006 investigators meeting at #sno2019!!" (@TimothyKruserMD)

"Coming soon. Interesting concept. #BN006 #toca511 #nrg19 #btsm" (@DNeuroonc)

"On #BN006 using #TOCA511, tumors will need to be 5cm or less & at least ~80% resection. Pts will need to be seen & CONSENTED prior to surgery. #btsm #NRG19 @BrainTumorDoc opening June 2019" (@AshleySumrallMD)

Clinical